Professional
Added to YB: 2026-04-14
Pitch date: 2026-04-10
TOI [neutral]
Starling Oncology, Inc.
+105.18%
current return
Author Info
No bio for this author
Company Info
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States.
Market Cap
$638.0M
Pitch Price
$3.09
Price Target
N/A
Dividend
N/A
EV/EBITDA
-77.56
P/E
-20.58
EV/Sales
1.19
Sector
Health Care Providers and Services
Category
turnaround
Cedar Grove Capital Management Portfolio Holding: The Oncology Institute, Inc.
TOI (holding update): Niche oncology platform delivering end-to-end cancer care via value-based care model, assuming risk for total patient outcomes vs fee-for-service. Aligns incentives across payers/physicians/patients, lowering costs while capturing economics across full value chain. Stock rebounded from 2024 lows on new mgmt driving topline growth via payer contracts & pharmacy segment expansion. Inflecting to adj EBITDA profitability, proving operating leverage as VBC model gains traction.
Read full article (1 min)